https://scholars.lib.ntu.edu.tw/handle/123456789/557883
標題: | Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors | 作者: | Dawood S. Chiu J.W.-Y. CHIUN-SHENG HUANG Nag S. Sookprasert A. Yap Y.-S. Md Yusof M. |
關鍵字: | Asia Pacific; Breast cancer; CDK4/6 inhibitor; endocrine therapy; hormone receptor positive; palbociclib; practical guidance | 公開日期: | 2020 | 出版社: | Taylor and Francis Ltd | 卷: | 36 | 期: | 8 | 起(迄)頁: | 1363-1373 | 來源出版物: | Current Medical Research and Opinion | 摘要: | Breast cancer is the most frequent cancer amongst women worldwide including in Asia where the incidence rate is rapidly increasing. Even with treatment, around 30% of patients with early breast cancer progress to metastatic disease, with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer the most common phenotype. First-line endocrine therapy targeting the estrogen receptor signaling pathway provides a median progression-free survival or time to progression of 6–15 months in HR + HER2- metastatic breast cancer. Recently, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, combined with endocrine therapy, have achieved more than two years median progression-free survival in HR + HER2- metastatic breast cancer. However, the characteristics of the Asian breast cancer population differ from those of Western populations and need to be considered when selecting a suitable treatment. Breast cancer is diagnosed at a younger age in Asian populations and late stage at presentation is generally more common in low-/middle-income countries than high-income countries. Consequently, the proportion of premenopausal women with metastatic breast cancer is higher in Asian compared with Western populations. While CDK4/6 inhibitors have been approved in the USA (FDA) since 2015, experience with them in Asia is more limited. We review the experience with the CDK4/6 inhibitor palbociclib in Asian patients with HR + HER2- metastatic breast cancer and provide guidance on the use of palbociclib in these patients. ? 2020 Informa UK Limited, trading as Taylor & Francis Group. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087624739&doi=10.1080%2f03007995.2020.1783646&partnerID=40&md5=27dd5f7df693064f55dc4ea6cb78f355 https://scholars.lib.ntu.edu.tw/handle/123456789/557883 |
ISSN: | 0300-7995 | DOI: | 10.1080/03007995.2020.1783646 | SDG/關鍵字: | abemaciclib; cyclin dependent kinase 4; cyclin dependent kinase 6; cyclin dependent kinase inhibitor; epidermal growth factor receptor 2; estrogen receptor; hormone receptor; palbociclib; ribociclib; cyclin dependent kinase 4; cyclin dependent kinase 6; epidermal growth factor receptor 2; ERBB2 protein, human; estrogen receptor; palbociclib; piperazine derivative; protein kinase inhibitor; pyridine derivative; Asian; cancer chemotherapy; cancer hormone therapy; drug efficacy; hormonal therapy; human; liver metastasis; metastatic breast cancer; ovary function; premenopause; Review; signal transduction; adult; breast tumor; female; metastasis; middle aged; mortality; pathology; Adult; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Middle Aged; Neoplasm Metastasis; Piperazines; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Receptors, Estrogen |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。